Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat Monotherapy and in Combination With Izalontamab Brengitecan in Advanced or Metastatic NSCLC
NCT06855771Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of navlimetostat in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective Response up to 3 years, Dose Limiting Toxicities up to 28 days and 7 more. Started Sep 2025; status: recruiting.
02
Drugs
navlimetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06855771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855771.